Erick Lucera, CFA
Erick Lucera, CFA joined the SAB board of directors in April 2023, bringing thirty years of financial, operational and investment experience in the biotechnology and medical device industry.
Mr. Lucera served as chief financial officer for AVEO Oncology, a commercial stage oncology-focused biopharmaceutical company, from January 2020 until February 2023, and subsequent to the close of its acquisition, worked on integration with LG Chem, Ltd.
Prior to that, he held chief financial officer and other senior roles at several biotechnology and medical device companies, including Valeritas (a publicly traded commercial-stage medical technology company where he led multiple successful public offerings) and at Viventia Bio (acquired by Eleven Biotherapeutics, Inc., now Sesen Bio, a biotechnology company focused on developing targeted protein therapeutics for the treatment of cancer). Early in his career, Mr. Lucera spent more than 15 years covering healthcare and the life sciences in investment management.
Mr. Lucera holds a CPH from Harvard University, as well as an MS from Boston College and an MBA from Indiana University Bloomington. He earned his BS in accounting from the University of Delaware. Additionally, Mr. Lucera currently holds a CFA designation. He previously held CMA and CPA designations, now expired.